Omega is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases.

This collaboration will leverage Novo Nordisk’s expertise in research and development within cardiometabolic diseases and Omega’s proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management.

Omega, Flagship’s Pioneering Medicines initiative, and Novo Nordisk will jointly advance this obesity management program through preclinical development and conduct foundational activities, after which point Novo Nordisk could further advance the program including through human proof-of-concept studies.

The Hogan Lovells team was led by partners Cullen Taylor (Northern Virginia) and Stephen Nicolai (Philadelphia), with support from senior attorney Melissa Schwaller (Houston), senior counsel Daniel Davidson (Washington, D.C.) and associate Estefania McCarroll (Northern Virginia).